Merck & Co., Inc. news

   Watch this stock
Showing stories 1 - 10 of about 161   

Articles published

MRK 59.17 +0.32 (0.54%)
price chart
Merck & Co. Inc. (MRK) Among Biggest DJIA Losers on August 21
Shares of Merck & Co. Inc. led all laggers on the Dow Thursday with a decline of 1.06%. The DJIA closed at 17,039.60, which is a 0.36% change from the previous day's close.
3 Reasons Merck & Co., Inc.'s Stock Could Rise
For investors lucky enough to have jumped into Merck (NYSE: MRK ) in 2009 at the tail end of the Great Recession you've seen an appreciation in your shares of near 100%.
Related articles »  
Why Wall Street Is Not Bearish On Merck
None of the analysts covering Merck & Co., Inc. (MRK) are bearish due to the company's strong drug pipeline. However, many are not completely sure of Merck's future and have a neutral stance on the pharmaceutical.
Merck & Co., Inc. (MRK): The Grand Daddy of Pharma
Right now, Merck & Co., Inc.(NYSE:MRK), this nation's second biggest pharmaceutical maker, is a curious animal: a value stock that's priced like a growth stock.
Merck & Co. Inc. (MRK) Among Biggest DJIA Losers on August 18
Shares of Merck & Co. Inc. led all laggers on the Dow Monday with a decline of 0.32%. The DJIA closed at 16,838.70, which is a 1.06% change from the previous day's close.
Related articles »  
Merck & Co. Inc. (MRK) Tops DJIA Gainers for August 22
The Dow closed at 17,001.20 on Friday, which is a -0.22% move from yesterday's close. Merck & Co. Inc. led all gainers with a 0.54% jump.
Merck's Sleeping Pill-Belsomra: Approved
Merck & Co., Inc. (MRK), the second-largest US pharmaceutical company, stock closed 1.44% higher yesterday, and continued to gain during extended trading, after the Food and Drug Administration (FDA) approved the company's experimental drug, ...
Merck & Co. Inc (NYSE:MRK) The Insomniac's Wish, Perrigo Company PLC ...  SmallCap Network
FDA Approves New Sleeping Drug From Merck  ABC News
Related articles »  
5 Things Merck & Co., Inc.'s Management Wants You to Know
In its second-quarter earnings results, released just two weeks ago, Merck reported a 1% decline in worldwide sales to $10.9 billion from the year-ago period, weighed-down by patent expirations and increasing competition, as its adjusted earnings per ...
Related articles »  
One Put, One Call Option To Know About for Merck & Co.
Consistently, one of the more popular stocks people enter into their stock options watchlist at Stock Options Channel is Merck & Co Merck & Co., Inc (NYSE: MRK). So this week we highlight one interesting put contract, and one interesting call contract ...
Related articles »  
Merck & Co., Inc. (MRK) Tops Q2 EPS by 5c
Merck & Co., Inc. (NYSE: MRK) reported Q2 EPS of $0.85, $0.05 better than the analyst estimate of $0.80. Revenue for the quarter came in at $10.93 billion versus the consensus estimate of $10.6 billion.
Merck & Co., Inc. (MRK) Releases FY14 Earnings Guidance  WKRB News
Merck & Co., Inc. Posts Higher Q2 Profits; Revenue Declines; Beats ...
Related articles »